209 results on '"Bensi M"'
Search Results
2. Treatment of patients with BRAFV600E-mutated metastatic colorectal cancer after progression to encorafenib and cetuximab: data from a real-world nationwide dataset
3. Chemotherapy Rechallenge or Reintroduction Compared to Regorafenib or Trifluridine/Tipiracil for Pretreated Metastatic Colorectal Cancer Patients: A Propensity Score Analysis of Treatment Beyond Second Line (Proserpyna Study)
4. Encorafenib plus cetuximab with or without binimetinib in patients with BRAF V600E-mutated metastatic colorectal cancer: real-life data from an Italian multicenter experience
5. Benthic foraminiferal assemblages and environmental drivers along the Kveithola Trough (NW Barents Sea)
6. Bottom current control on sediment deposition between the Iselin Bank and the Hillary Canyon (Antarctica) since the late Miocene: An integrated seismic-oceanographic approach
7. Hydraulic compatibility of nonwoven conical filters with a backfill material.
8. Conversion Therapy With Encorafenib and Cetuximab for Chemo-Refractory BRAF V600E-Mutated Liver-Limited Colorectal Cancer Metastasis: The First Case Report
9. Hydraulic compatibility of nonwoven conical filters with a backfill material
10. P-97 DNA damage repair (DDR) germline mutations (GMs) in pancreatic ductal adenocarcinoma (PDAC): A mono-institutional retrospective study
11. P-148 The impact of second-line treatment after fist-line cisplatin plus gemcitabine in advanced biliary tract cancers: A mono-institutional retrospective study
12. P-83 The impact of the multidisciplinary team (MDT) in the management of colorectal cancer (CRC)
13. P-155 Adjuvant therapy (AT) in patients (pts) with radically resected ampullary adenocarcinoma (AA): A monocentric retrospective analysis
14. Management of single pulmonary metastases from colorectal cancer: State of the art
15. Variation of minisatellites in chemically induced mutagenesis and in gene amplification
16. Role of chemoradiation (CRT) in the adjuvant treatment of radically resected pancreatic cancer (PC) patients (pts): a mono-institutional retrospective analysis
17. Progetto CASSANDRA: AdvanCing knowledge on the present Arctic Ocean by chemical-phySical, biogeochemical and biological obServAtioNs to preDict the futuRe chAnges
18. P-74 The impact of first-line chemotherapy in elderly patients with advanced pancreatic cancer: A mono-institutional retrospective study
19. O-12 Phase II study of preoperative chemoradiotherapy plus avelumab in patients with locally advanced rectal cancer: The AVANA study
20. 648P Medium to long-term effects of the COVID-19 pandemic on colorectal cancer diagnosis and management in Italy: Preliminary findings from an updated analysis of the real-world multicenter COVID-DELAY study
21. 1679P Comparison of first-line chemotherapy regimens in unresectable locally advanced or metastatic pancreatic cancer: A systematic review and network meta-analysis
22. 124P Clinicopathological nomogram for predicting fibroblast growth factor receptor 2 (FGFR2) gene fusion/rearrangement (F/R) in intrahepatic cholangiocarcinoma (iCCA)
23. 2062P The psychological distress (PsyD) evaluation in pancreatic cancer (PC) patients (pts): A mono-institutional analysis
24. Cruise Report EUROFLEETS2 ESAW-2 ‘Evolution and spreading of the Southern Adriatic Waters'(ESAW) ESAW-2
25. SO-28 FOLFOXIRI plus bevacizumab and atezolizumab as upfront treatment of unresectable mCRC patients: Updated and overall survival results of the phase II randomized AtezoTRIBE study
26. SO-3 Clinical relevance and actionability of BRAF alterations in advanced biliary tract cancer: Preliminary results from the multicenter B-REAL study
27. P-381 Management of EaRly-onset MetastatIc cOlorectal caNcEr (ERMIONE): A single institution analysis
28. P-275 FOLFOX versus FOLFIRI as second-line treatment after cisplatin-gemcitabine in patients with advanced biliary tract cancers
29. P-177 Italian real world artificial intelligence (AI) based analysis of EaRly-onset COLorEctal cancer: The ERCOLE study
30. P-153 Focus on RAS codon 61 mutations in metastatic colorectal cancer (mCRC): A retrospective analysis
31. P-110 Epidemiological and clinicopathological features of early- (EOPC) and late-onset pancreatic cancer (LOPC) patients (pts): A mono-institutional retrospective analysis
32. P-90 Prognostic impact of depth of response (DpR) and early tumour shrinkage (ETS) in patients (pts) with BRAFV600E mutated (mut) metastatic colorectal cancer (mCRC) receiving targeted therapy (TT) as second-line treatment
33. PD-21 Exploring the prognostic and predictive impact of genomic loss of heterozygosity (LOH) in metastatic colorectal cancer (mCRC) patients
34. PD-17 Multicentric prospective study assessing clinical benefit of targeted treatment for patients with biliary tract cancers
35. Bayesian network modeling of system performance
36. P-164 The role of response as a predictor of improved outcome in advanced pancreatic cancer patients treated with first-line gemcitabine plus nab-paclitaxel
37. P-102 The impact of a multidisciplinary approach in the management of pancreatic disease
38. P-103 The role of primary tumor site as a prognostic factor after resection of colorectal liver metastases: A mono-institutional cohort study
39. P-161 Efficacy of third-line anti-EGFR-based treatment versus regorafenib/TAS-102 (R/T) according to primary tumor site in RAS/BRAF wild-type metastatic colorectal cancer patients
40. P-152 The impact of 2nd-line treatment after 1st-line gemcitabine plus nab-paclitaxel in advanced pancreatic cancer patients
41. Evaluation of the clinical profile before the onset of psychosis. A study on 296 in-patients with diagnosis of “non-affective psychotic disorder”: OR096
42. The role of the intensive care unit in real-time surveillance of emerging pandemics: the Italian GiViTI experience
43. Spitsbergen Oceanic and Atmospheric interactions
44. Phase II study of preoperative (PREOP) chemoradiotherapy (CTRT) plus avelumab (AVE) in patients (PTS) with locally advanced rectal cancer (LARC): The AVANA Study
45. Role of chemoradiation (CRT) in the adjuvant treatment of radically resected pancreatic cancer (PC) patients (pts): a mono-institutional retrospective analysis
46. Efficacy of retreatment with anti-EGFRs in metastatic colorectal cancer is not predictable by clinical factors related to prior lines of therapy: a multi-institutional analysis
47. Chemotherapy rechallenge or reintroduction, regorafenib, and TAS-102 for metastatic pretreated colorectal cancer patients: a propensity score analysis of treatment beyond the second line (PROSERpINA Study)
48. Clinical, pathological, and prognostic features of rare BRAF mutations in metastatic colorectal cancer: a bi-institutional retrospective analysis (REBUS study)
49. Variation of minisatellites in chemically induced mutagenesis and in gene amplification
50. PTEN in colorectal cancer: Shedding light on its role as predictor and target
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.